CUVRIOR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CUVRIOR (CUVRIOR).
CUVRIOR (trientine) is a copper-chelating agent that forms stable complexes with copper, enhancing its excretion in urine. It also reduces intestinal absorption of copper.
| Metabolism | Metabolized mainly by conjugation and oxidation; minor involvement of CYP450 enzymes. |
| Excretion | Primarily hepatobiliary; unchanged drug and metabolites excreted in feces. Renal elimination accounts for <5% of the administered dose. |
| Half-life | Terminal elimination half-life is approximately 0.9–1.5 hours; however, pharmacodynamic effects (copper mobilization) persist for 24–48 hours. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd is approximately 0.2–0.3 L/kg, indicating distribution largely confined to plasma and extracellular fluid. |
| Bioavailability | Not administered orally due to poor absorption; bioavailability by oral route is negligible. |
| Onset of Action | Intravenous administration: increase in urine copper excretion observed within 1–2 hours. |
| Duration of Action | Urine copper excretion returns to baseline within 24–48 hours; clinical effect on hepatic copper stores may last several days. |
300 mg subcutaneously once daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m²) or end-stage renal disease. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; clinical studies included a limited number of patients aged ≥65 years, with no overall differences in safety or efficacy observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CUVRIOR (CUVRIOR).
| Breastfeeding | It is unknown whether trientine is excreted in human milk. Caution should be exercised when administered to a nursing woman. The M/P ratio is not established. Given the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | CUVRIOR (trientine) is classified as Pregnancy Category C. In animal studies, trientine has been shown to be embryocidal and teratogenic at doses similar to the human dose. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Copper deficiency from aggressive chelation may increase teratogenic risk; therefore, maintaining copper levels within the therapeutic range is critical. First trimester: highest risk for malformations; second and third trimesters: risk of fetal copper deficiency and impaired development if maternal copper is overchelated. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to trientine or any component","Rheumatoid arthritis (due to potential exacerbation of symptoms)","Use in pregnancy only if clearly needed"]
| Precautions | ["Monitor for iron deficiency due to copper chelation","May cause lupus-like syndrome","Monitor liver function tests","Use with caution in patients with renal impairment"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum copper and zinc levels regularly (e.g., every 2-4 weeks) to maintain copper in the therapeutic range (typically 20-50 mcg/dL) and avoid deficiency. Monitor for signs of copper deficiency (anemia, leukopenia, bone marrow suppression). Fetal monitoring includes serial ultrasound for growth and anatomy, and consider fetal echocardiography due to potential cardiac effects. Monitor maternal neurological status if indicated. |
| Fertility Effects | Animal studies have shown no impairment of fertility at therapeutic doses. However, copper deficiency from overchelation can impair reproductive function. In humans, no specific fertility studies are available; Wilson disease itself may affect fertility. Adequate copper maintenance is essential for normal reproductive function. |